A phase II, multicenter, open-label, single-arm study of berzosertib plus topotecan in patients with relapsed platinum-resistant small-cell lung cancer (DDRiver SCLC 250)
一项 II 期、多中心、开放标签、单臂研究，评估 berzosertib 联合拓扑替康治疗复发性铂耐药小细胞肺癌患者的疗效（DDRiver SCLC 250）。
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105918
Navarro, A; Thomas, A; Cheng, Y; Chen, Y; Reguart, N; Yoshida, T; Cousin, S; Dong, X; Yamamoto, N; Cappuzzo, F; Hallwachs, R; Bolleddula, J; Sarholz, B; Grombacher, T; Otte, M; Gounaris, I; Ferrer, J; Moulin, C; Paz-Ares, L
